Japan-based Solasia Pharma has started an Asian Multinational Phase II trial of SP-02 (darinaparsin) for injection (SP-02L) to treat relapsed and refractory peripheral T-cell lymphoma (PTCL).

The trial is designed to evaluate the efficacy and safety of SP-02L monotherapy, and is being carried out in Japan, South Korea, Taiwan and Hong Kong.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SP-02 is a new mitochondrial-targeted agent being developed to treat various hematologic and solid cancers.

The company noted that in a US Phase II trial, SP-02 showed clinical activity in lymphoma, in particular PTCL.

Safety and potential efficacy against PTCL have also been demonstrated in a Phase I trial carried out in Japan and South Korea.

Based on the Phase II result, the company plans to file for registration in Japan, South Korea, Taiwan and Hong Kong.

The Japanese firm secured an exclusive worldwide licence to develop and commercialise SP-02 from Ziopharm Oncology.

The company aims to accelerate patient’s access to oncology therapies through development and specialised commercialisation across Japan, China and other Asian countries.

Last August, the company provided Series D financing of JPY2.08bn ($18.3m) for the launch of Sancuso and further advance clinical development of its existing pipeline.